Stifel is moving off the sidelines when it comes to Biogen . The investment firm upgraded the biotech stock to buy from hold. It also hiked...
Large-cap biotech Regeneron Pharmaceuticals is judged to be in the throes of a “bearish-to-bullish” reversal, with the prospective completion of the bottoming-out process implying a move to...
There’s a beaten-down biotech that may be worth the shot. The biotech sector has been on fire as of late. The SPDR S & P Biotech...
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Denmark’s Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker...
A Debut Biotech petri dish. Courtesy: Debut Biotech In a lab tucked away in southern California, scientists at Debut Biotech are testing molecules using advanced biotechnology...
Investors are noticing ripe opportunity in Cytokinetics, a late-stage biopharma company targeting medicines for specialty heart diseases, that has seen shares skyrocket in recent months. Shares...
BioAge Labs shares have ample room to run as the biotechnology firm’s obesity treatment is poised to gain traction in the booming weight management solutions market,...
